51 studies found for:    SGN-35
Show Display Options
Rank Status Study
1 Recruiting Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: brentuximab vedotin (SGN-35);   Drug: Brentuximab Vedotin (SGN-35)
2 Terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-35;   Drug: gemcitabine
3 Recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
4 Completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Conditions: Lymphoma, Non-Hodgkin;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: SGN-35
5 Active, not recruiting A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin;   Drug: placebo
6 Completed Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
7 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole
8 Active, not recruiting
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
9 Recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
10 Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Conditions: Lymphoma, Non-Hodgkin;   Cutaneous Lymphoma;   Cutaneous T Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Brentuximab vedotin
11 Recruiting Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Condition: Germ Cell Cancer
Intervention: Drug: Brentuximab Vedotin
12 Completed
Has Results
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
13 Active, not recruiting
Has Results
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Condition: Disease, Hodgkin
Intervention: Drug: brentuximab vedotin
14 Withdrawn Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: vinblastine;   Drug: dacarbazine;   Drug: brentuximab vedotin;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin hydrochloride;   Drug: vinblastine;   Drug: dacarbazine;   Procedure: quality-of-life assessment;   Genetic: DNA analysis;   Genetic: RNA analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: polymorphism analysis
17 Not yet recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Recurrent/Refractory Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Biological: bleomycin sulfate;   Drug: vincristine sulfate;   Drug: etoposide;   Drug: prednisone;   Drug: cyclophosphamide;   Drug: brentuximab vedotin;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
18 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
19 Recruiting Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
20 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years